At the news
? BEARISHIMPACT 6/10 424B5 filed May 20, 2026 at 16:12 ET
Annovis Bio is raising approximately $13.8M in net proceeds through a dilutive offering of 7.9M shares and warrants, priced at $1.90/unit (vs. last sale $1.94). The company has a going concern warning with only $14.2M cash (as of Mar 31, 2026) and an accumulated deficit of $181.3M. This capital raise, following a poor Q1 earnings report, underscores acute funding needs and dilutes existing shareholders by ~23% (excluding warrants). Traders should expect near-term price pressure given the minimal premium to market and ongoing cash burn.
- Offering 7,895,000 shares of common stock plus warrants to purchase up to 7,105,500 shares at $2.25 exercise price, 6-year term
- Combined offering price $1.90 per unit, net proceeds ~$13.8M
- Cash and cash equivalents of $14.2M as of March 31, 2026; company believes runway only extends to Q4 2026
- Going concern warning from independent auditor; accumulated deficit of $181.3M
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access